AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 66 min read$ASTH

Astrana Health, Inc. (ASTH): Results of Operations and Financial Condition

Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adju

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ASTH
Bullish
high confidence
Mentioned
$ASTH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASTHBullishHigh
01

Why it matters

The key tradable items are the reported Q2 financials and the updated 2026 adjusted EBITDA guidance, which can shift valuation multiples and expectations for cash generation.

02

Market read

Strong Q2 growth and profitability metrics, plus updated guidance ranges for Q3 and full-year 2026, create a clear catalyst for repricing ASTH expectations.

03

What to watch

Traders may focus on the sustainability of free cash flow and the drivers behind the Care Partners revenue growth, not just top-line and adjusted EBITDA.

Relevance 7/10Novelty 9/10Timing: after-hours/filing today, ahead of the Aug 6 conference call

Background

This is an SEC 8-K with Exhibit 99.1 covering Astrana’s Q2 2026 results, operating highlights, and updated guidance, plus a same-day earnings call.

Company-level read

Ticker impact

$ASTHBullishHigh confidence
Context

Astrana reported Q2 2026 revenue of $972.5M (+49% YoY) and raised 2026 adjusted EBITDA guidance, alongside updated Q3 revenue and EBITDA ranges.

Expected impact

Likely positive bias for the stock into the next trading session as traders reprice 2026 EBITDA and cash flow expectations.

Evidence & confidence

The filing discloses multiple hard datapoints (revenue, net income, adjusted EBITDA, free cash flow) and provides explicit updated guidance ranges for Q3 and full-year 2026.

Market effects

Sector

Reinforces demand for physician-centric, technology-enabled value-based care platforms, potentially supporting sentiment toward similar healthcare services models.

Regional

Limited direct regional spillover; primarily company-specific.

Global

Low global relevance beyond US healthcare services investors.

Counterpoint

What could challenge this read

Guidance is still a range and the company notes no assurance results won’t differ materially; growth could normalize after reinvestment.

Key entities

  • company
    Astrana Health, Inc.

    NASDAQ-listed physician-centric, technology-enabled healthcare company reporting Q2 2026 results and updated guidance.

  • executive
    Brandon Sim

    President and CEO quoted on performance and guidance confidence.

Read at source← All news

Related articles

SEP 15
$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min
AUG 13
$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

fool.com7 min
AUG 7
$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

yahoo.com4 min
AUG 6
$ASTHMed

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

financialcontent.com6 min